Indobufen

Indobufen is a small molecule, non-steroidal anti-inflammatory drug (NSAID) that acts as a reversible inhibitor of platelet aggregation. Its primary mechanism of action is the reversible and non-competitive inhibition of cyclooxygenase-1 (COX-1), which suppresses the production of thromboxane A2, a key mediator in platelet activation and aggregation[6][8]. Indobufen also reduces levels of platelet factor 3 and platelet factor 4, thereby inhibiting the activation of coagulation factors II (prothrombin) and X, contributing to its anticoagulant effects[5][6]. Clinically, indobufen is used to prevent thrombosis in patients at high risk for cardiovascular events such as myocardial infarction or stroke, as well as for the prevention of coronary and peripheral artery occlusion. It has also been studied for supportive care in atrial fibrillation and prevention of embolic events in heart disease[1][4][7]. Developed and manufactured by Recordati, Indobufen is distinguished from other NSAIDs by its reversible inhibition profile on COX-1. It is not widely available globally but has established use in several countries for cardiovascular indications.

Brand names

IbustrinIbu-strin

Other names

indobuprofene